MacroGenics (MGNX) Jumps: Stock Up 7.5% - Tale of the Tape

by Zacks, Benzinga Contributor
April 24, 2014 10:21 AM | 1 min read |
MacroGenics, Inc. MGNX was a big mover last session, as its shares rose nearly 8% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This reverses the downtrend for the company, as the stock is now down roughly 39% in the past one-month timeframe.

In the last 30 days, the company has not seen any estimate revision and the Zacks Consensus Estimate also remained unchanged. However, yesterday's price action is encouraging, so make sure to keep a close watch on this firm in the near future.

MacroGenics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Better-ranked medical stocks include Edwards Lifesciences Corp. EW, Enzymotec Ltd. ENZY and Venaxis, Inc. APPY. While Edwards Lifesciences and Venaxis carry a Zacks Rank #2 (Buy), Enzymotec sports a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

 
VENAXIS INC APPY: Get Free Report
 
ENZYMOTEC LTD ENZY: Free Stock Analysis Report
 
EDWARDS LIFESCI EW: Free Stock Analysis Report
 
MACROGENICS INC MGNX: Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!